


PRODUCT: BTK Inhibitor PCI-32765

ALTERNATE NAME: 2-propen-1-one, 1-((3R)-3-(4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo(3,4-d)pyrimidin-1-yl)-1-piperidinyl)-; Ibrutinib; CRA-032765

CATALOG #: 2298-5, 25

AMOUNT: 5 mg, 25 mg

STRUCTURE:



MOLECULAR FORMULA: C₂₅H₂₄N₆O₂

MOLECULAR WEIGHT: 440.50

CAS NUMBER: 936563-96-1

APPEARANCE: White solid

SOLUBILITY: DMSO (>80 mg/ml)

PURITY: ≥98% by HPLC

STORAGE: At -20°C. Protect from air and light

DESCRIPTION: A potent and highly selective small-molecule inhibitor of Bruton's tyrosine kinase (BTK) (IC₅₀ = 0.5 nM) with potential antineoplastic activity. It binds to and irreversibly inhibits BTK activity, thereby preventing both B-cell activation and B-cell-mediated signaling. This leads to an inhibition of the growth of malignant B cells that overexpress BTK.

REFERENCE: Honigberg, L.A., *et al.* (2010). *Proc. Natl. Acad. Sci. USA* **107**, 13075-13080.

HANDLING: Do not take internally. Wear gloves and mask when handling the product! Avoid contact by all modes of exposure.

RELATED PRODUCTS:

ABT-869 (Cat. No. 1615-1, 5)

Angiostatin, Human (Cat. No. 4919-100, 500)

Angiostatin, K1-3, Human (Cat. No. 4920-20, 100, 500)

BAY 43-9006 (Cat. No. 1594-25, 100)

BAY 43-9006, Free base (Cat. No. 2142-25, 100)

EZSolution™ BAY 43-9006 (Cat. No. 2031-25)

BIBF1120 (Cat. No. 2167-5, 25)

Carbozantinib (Cat. No. 1935-5, 25)

Cediranib (Cat. No. 1613-1, 5)

Endostatin, human recombinant (Cat. No. 4759-20, 100, 100)

GSK1904529A (Cat. No. 2286-5, 25)

GW-786034 (Cat. No. 1916-5, 25)

Motesanib (Cat. No. 2022-5, 25)

SU 1498 (Cat. No. 1836-1, 5)

Thiabendazole (Cat. No. 2161-1G)

Tranilast (Cat. No. 1876-10, 50)

SU 6668 (Cat. No. 1931-5, 25)

Vandetanib (Cat. No. 1751-25, 100)

Vatalanib, dihydrochloride (Cat. No. 2025-5, 25)

Vatalanib, Free base (Cat. No. 2026-5, 25)

USAGE: **FOR RESEARCH CH USE ONLY! Not to be used in humans**